Maoxiao Nie

Maoxiao Nie

Auto-generated profile, based on publicly available information

Maoxiao Nie

Department of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
XCXue Chen
Xue Chen
XZXuehui Zhang
Xuehui Zhang
YYYunfeng Yan
Yunfeng Yan
XZXin Zhao
Xin Zhao
MNMaoxiao Nie
Maoxiao Nie
QZQuanming Zhao
Quanming Zhao
Background. Many studies have compared the outcomes of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) for complex coronary artery disease (CAD). However, no trials have focused on young patients (<45 years) with complex CAD. We conducted a retrospective evaluation to compare the outcomes of a second-generation drug-eluting stent (DES) and CABG in young patients with LM or three-vessel disease. Methods. In young patients with complex CAD who underwent PCI or CABG, a Kaplan-Meier analysis and Cox regression before and after propensity score matching were used to compare major adverse cardiac and cerebrovascular events (MACCE), including myocardial infarction (MI), stroke, death, and repeat revascularization. Results. During follow-up, MACCE occurred in 20.5% of patients in the PCI group and 8.6% of patients in the CABG group (hazard ratio (HR): 3.263, 95% confidence interval (CI): 1.379 to 7.722, p=0.007). Repeat revascularization occurred more frequently in the PCI group (18.9% vs. 3.7%, respectively, HR: 6.968, 95% CI: 2.036 to 23.842, p=0.002). There were no significant differences in the other endpoints. After propensity score matching, no conclusions were modified. Conclusions. In young patients with LM or three-vessel disease, PCI showed a higher incidence of MACCE, which was mainly driven by repeat revascularization. However, this did not translate into hard endpoint differences. Therefore, PCI is an alternative treatment to CABG in young patients with complex CAD.

1 September 2021 in Vascular
Verified
Journal Article
Closed access
PDF file
XZXuehui Zhang
Xuehui Zhang
XCXue Chen
Xue Chen
ZLZhe Liang
Zhe Liang
MNMaoxiao Nie
Maoxiao Nie
YYYunfeng Yan
Yunfeng Yan
QZQuanming Zhao
Quanming Zhao
It is not yet clear whether plaque inflammation and cardiovascular events are reduced further when pioglitazone and atorvastatin are combined. Our study aimed to determine whether pioglitazone combined with atorvastatin can restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model Thirty rabbits were randomly divided into an atherosclerosis group, an atorvastatin group, and an atorvastatin plus pioglitazone group. The atherosclerosis model was induced using balloon injury and feeding a high-fat diet. Plasma samples were then used to analyze glucose, triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), and matrix metalloproteinase-9 (MMP-9). The area percentage of atherosclerotic plaques was analyzed by hematoxylin-eosin staining. The relative reductions in TG and LDL-C and the increase in HDL-C levels were significantly greater in the combination therapy group than in the atorvastatin monotherapy group (TG: −33.60 ± 7.17% vs −24.16 ± 8.04%, p < 0.001; LDL-C: −42.89 ± 1.63% vs −37.13 ± 1.35%, p < 0.001; and HDL-C: 25.18 ± 5.53% vs 10.43 ± 6.31%, p < 0.001). The relative reductions in hs-CRP and MMP-9 levels were significantly greater in the combination therapy group than in the atorvastatin monotherapy group (−69.38 ± 1.06% vs-53.73 ± 1.92%, p < 0.001; −32.77 ± 2.49% vs −13.36 ± 1.66%, p < 0.001). The area percentage of atherosclerotic plaques was significantly smaller in the atorvastatin group (47.75%, p < 0.05) and in the atorvastatin plus pioglitazone group (22.57%, p < 0.05) than in the atherosclerosis group (84.08%, p < 0.05) We can thus conclude that the combination treatment of atorvastatin and pioglitazone provided additive benefits on inflammatory parameters and lipid metabolism. Pioglitazone combined with atorvastatin can further restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model.

18 July 2025 in Health Science Reports
Verified
Journal Article
Open access
XZXiao‐Xia Zhang
Xiao‐Xia Zhang
QCQing Chen
Qing Chen
XZXiao‐Jiang Zhang
Xiao‐Jiang Zhang
YDYao‐Dong Ding
Yao‐Dong Ding
GWguozhong wang
guozhong wang
YZYong Zeng
Yong Zeng
Background and Aims: Treatment of drug‐eluting stents (DES) in‐stent restenosis (ISR) was challenging. Neoatherosclerosis (NA) occurs earlier and more frequently in DES‐ISR. This study aims to analyze the effect of neoatheroma morphology and intervention‐associated neoatheroma intima rupture on intervention strategies and clinical outcomes in patients with DES‐ISR. Methods: We retrospectively analyzed 56 consecutive patients with symptomatic DES‐ISR and optical coherence tomography (OCT) verified in‐stent NA who had been treated by repeat stenting or drug‐coated balloon (DCB). Patients were divided into two groups according to whether there was severe neoatheroma intima rupture (SNIR) after balloon angioplasty. Characteristics of the neointima were analyzed. Intervention strategies and clinical outcomes were compared between the two groups. Results: SNIR occurred in 29 patients after balloon angioplasty. Repeat stenting was more frequent in these patients (48.3% vs. 7.4%, p = 0.009). The incidence of target lesion revascularization (TLR) was significantly higher in patients with SNIR (37.9% vs. 11.1%, p = 0.021), SNIR was an independent risk factors of TLR (HR: 3.997, p = 0.034). In patients with SNIR, repeat stenting significantly reduced the rate of TLR than DCB (14.3% vs. 60.0% p = 0.014). The lipid pool depth and the maximum lipid arc of the neoatheroma were significantly larger and the percentage of the frame with neoatherosclerosis was significantly higher in patients with SNIR (510.1 ± 162.7 vs. 370.7 ± 129.6 µm, p = 0.001; 155.5 ± 41.6 vs. 107.7 ± 44.4 degrees, p = 0.000; and 28.2% ± 14.3% vs. 16.0% ± 9.5%, p = 0.001, respectively). Multivariate logistic regression demonstrated that HbA1C (OR = 1.868, p = 0.044) and time from PCI to ISR (OR = 1.278, p = 0.026) were independent predictors of SNIR. Conclusions: Intervention‐associated severe neoatheroma rupture increased the risk of recurrent TLR, repeat stenting was more effective than DCB in such patients. Neoatherosclerosis with a significant lipid pool is closely related to intervention‐associated SNIR.